Reminder of this systematic review (LANCET) by Lim et al. showing that all COVID mRNA gene injection Vaccines Perform Worse Than Natural Immunity Against COVID (original strain & Alpha, Beta & Delta)

by Paul Alexander

This review summarized what we have been screaming about for 2 years now, in that this COVID mRNA technology gene injection failed day one, never protected the upper airways & was deadly, not new info

‘Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks.’

Researchers ‘identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant.’

‘The data in the above figure indicate that prior infection of COVID offers significantly high levels of protection against reinfection (over 80 percent), symptomatic infection (over 82 percent), and severe disease (over 78 percent) for the original strain and the Alpha, Beta, and Delta variants. The protection effectiveness dropped for Omicron variants, down to 44 percent and 45 percent for reinfection and symptomatic infection. But the effectiveness against severe diseases was still above 80 percent for Omicron.’

‘Pooled effectiveness against re-infection by the omicron BA.1 variant was 45·3% (95% uncertainty interval [UI] 17·3–76·1) and 44·0% (26·5–65·0) against omicron BA.1 symptomatic disease. Mean pooled effectiveness was greater than 78% against severe disease (hospitalization and death) for all variants, including omicron BA.1. Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78·6% (49·8–93·6) at 40 weeks. Protection against re-infection by the omicron BA.1 variant declined more rapidly and was estimated at 36·1% (24·4–51·3) at 40 weeks. On the other hand, protection against severe disease remained high for all variants, with 90·2% (69·7–97·5) for ancestral, alpha, and delta variants, and 88·9% (84·7–90·9) for omicron BA.1 at 40 weeks.’

One may argue that the Omicron sub-variant was so sufficiently different due to the large number of mutations on the target spike antigen and its receptor binding sites/epitopes, that it is as if our immune systems were seeing an entirely different variant/strain etc. for the first time. Yet remarkably in that too, there is natural immunity broad protection.


These potent natural immunity findings mirror those reported by Lin et al. in children:

‘For children 5–11 years of age, the effectiveness of primary vaccination against infection was 59.9% (95% confidence interval [CI], 58.5 to 61.2), 33.7% (95% CI, 32.6 to 34.8), and 14.9% (95% CI, 12.3 to 17.5) at 1, 4 and 10 months after the first dose; the effectiveness of a monovalent or bivalent booster dose after 1 month was 24.4% (95% CI, 14.4 to 33.2) or 76.7% (95% CI, 45.7 to 90.0); and the effectiveness of omicron infection against reinfection was 79.9% (95% CI, 78.8 to 80.9) and 53.9% (95% CI, 52.3 to 55.5) after 3 and 6 months, respectively. For children 0–4 years of age, the effectiveness of primary vaccination against infection was 63.8% (95% CI, 57.0 to 69.5) and 58.1% (95% CI, 48.3 to 66.1) at 2 and 5 months after the first dose, and the effectiveness of omicron infection against reinfection was 77.3% (95% CI, 75.9 to 78.6) and 64.7% (95% CI, 63.3 to 66.1) after 3 and 6 months, respectively.’